Strs Ohio cut its position in Humana Inc (NYSE:HUM) by 56.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,372 shares of the insurance provider’s stock after selling 76,961 shares during the quarter. Strs Ohio’s holdings in Humana were worth $22,127,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Maverick Capital Ltd. raised its stake in Humana by 150.9% in the second quarter. Maverick Capital Ltd. now owns 1,550,726 shares of the insurance provider’s stock valued at $411,408,000 after buying an additional 932,778 shares during the period. Boston Partners increased its holdings in shares of Humana by 136.6% during the 3rd quarter. Boston Partners now owns 1,370,432 shares of the insurance provider’s stock worth $350,758,000 after acquiring an additional 791,163 shares during the last quarter. California Public Employees Retirement System increased its holdings in shares of Humana by 8.6% during the 3rd quarter. California Public Employees Retirement System now owns 850,334 shares of the insurance provider’s stock worth $217,405,000 after acquiring an additional 67,252 shares during the last quarter. Diamond Hill Capital Management Inc. increased its holdings in shares of Humana by 126.0% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 739,564 shares of the insurance provider’s stock worth $189,084,000 after acquiring an additional 412,379 shares during the last quarter. Finally, Voya Investment Management LLC raised its stake in Humana by 1,216.6% in the 3rd quarter. Voya Investment Management LLC now owns 685,265 shares of the insurance provider’s stock valued at $175,201,000 after acquiring an additional 633,216 shares during the period. Institutional investors and hedge funds own 94.59% of the company’s stock.
NYSE:HUM opened at $356.90 on Monday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.83 and a current ratio of 1.83. The firm has a market cap of $47.26 billion, a price-to-earnings ratio of 18.96, a P/E/G ratio of 1.39 and a beta of 0.92. Humana Inc has a 52 week low of $225.65 and a 52 week high of $376.39. The firm’s 50-day simple moving average is $362.57 and its 200 day simple moving average is $308.83.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.58 by $0.45. Humana had a net margin of 4.06% and a return on equity of 22.32%. The firm had revenue of $16.24 billion for the quarter, compared to analyst estimates of $16.15 billion. During the same quarter in the prior year, the business posted $4.58 EPS. The business’s revenue was up 14.3% compared to the same quarter last year. Sell-side analysts anticipate that Humana Inc will post 17.77 EPS for the current year.
In related news, insider Elizabeth D. Bierbower sold 5,347 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $370.00, for a total transaction of $1,978,390.00. Following the completion of the sale, the insider now owns 23,439 shares of the company’s stock, valued at $8,672,430. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Elizabeth D. Bierbower sold 14,655 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $351.42, for a total transaction of $5,150,060.10. Following the sale, the insider now directly owns 21,985 shares of the company’s stock, valued at approximately $7,725,968.70. The disclosure for this sale can be found here. Insiders have sold 45,294 shares of company stock worth $15,894,412 in the last three months. 0.54% of the stock is currently owned by company insiders.
HUM has been the subject of several research reports. Credit Suisse Group raised their price target on Humana from $378.00 to $400.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. JPMorgan Chase & Co. upped their price objective on shares of Humana from $437.00 to $448.00 and gave the company an “overweight” rating in a report on Friday, January 3rd. Argus increased their price objective on shares of Humana to $370.00 and gave the company a “buy” rating in a research report on Wednesday, November 20th. ValuEngine cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, December 4th. Finally, SunTrust Banks reaffirmed a “hold” rating and set a $370.00 target price on shares of Humana in a report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Humana has an average rating of “Buy” and an average target price of $361.31.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.